Trial Profile
A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CASPIAN
- Sponsors AstraZeneca; AstraZeneca AB
- 19 Dec 2023 Planned End Date changed from 29 Dec 2023 to 29 Mar 2024.
- 26 Oct 2023 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 06 Oct 2023 Results exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden , published in the Clinical Cancer Research